Literature DB >> 1422237

Classification of eye changes of Graves' disease.

.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1422237     DOI： 10.1089/thy.1992.2.235

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  30 in total

1.  Circulating endothelium-related adhesion molecules in black South African patients with Graves' disease.

Authors:  V R Panz; F J Raal; J R Wall; B I Joffe
Journal:  Endocrine       Date:  2000-02       Impact factor: 3.633

2.  Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.

Authors:  T-C Chang; S-L Liao
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

3.  Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.

Authors:  B Gopinath; R Musselman; N Beard; S El-Kaissi; J Tani; C-L Adams; J R Wall
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

4.  The use of colour slides in the assessment of changes in soft-tissue involvement in Graves' ophthalmopathy.

Authors:  M N Gerding; M F Prummel; R Kalmann; L Koornneef; W M Wiersinga
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

5.  DEGRO practical guidelines for the radiotherapy of non-malignant disorders - Part IV: Symptomatic functional disorders.

Authors:  Gabriele Reinartz; Hans Theodor Eich; Fabian Pohl
Journal:  Strahlenther Onkol       Date:  2014-12-09       Impact factor: 3.621

6.  Imaging biomarkers in thyroid eye disease and their clinical associations.

Authors:  Shikha Chaganti; Katrina Nelson; Kevin Mundy; Robert Harrigan; Robert Galloway; Louise A Mawn; Bennett Landman
Journal:  J Med Imaging (Bellingham)       Date:  2018-10-16

7.  Early macular and peripapillary vasculature dropout in active thyroid eye disease.

Authors:  Mansoreh Jamshidian Tehrani; Zahra Mahdizad; Abolfazl Kasaei; Masoud Aghsaei Fard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-08-23       Impact factor: 3.117

8.  Quality of life in patients with Graves ophthalmopathy.

Authors:  R Patrick Yeatts
Journal:  Trans Am Ophthalmol Soc       Date:  2005

9.  High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy.

Authors:  P E Macchia; M Bagattini; G Lupoli; M Vitale; G Vitale; G Fenzi
Journal:  J Endocrinol Invest       Date:  2001-03       Impact factor: 4.256

10.  Risk factors associated with the severity of thyroid-associated orbitopathy in Korean patients.

Authors:  Ji Hwan Lee; Sang Yeul Lee; Jin Sook Yoon
Journal:  Korean J Ophthalmol       Date:  2010-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.